“最毒乳腺癌”免疫治疗为何耐药？最新研究：“元凶”是肿瘤中的感觉神经

Core Insights - The latest research reveals that sensory nerves within tumors are a key factor causing immune therapy resistance in some triple-negative breast cancer patients, which is known for its high malignancy and low survival rates [1][2]. Group 1: Research Findings - The study, led by a team from Fudan University, identifies that sensory nerves in triple-negative breast cancer tumors create a barrier that prevents immune cells from effectively penetrating the tumor [2]. - A significant correlation was found between the presence of peripheral nerve invasion in pathology samples and poor patient prognosis, indicating that this is an important signal for predicting ineffective immune therapy [2]. - The research indicates that when sensory nerves are active, they form a dense matrix barrier within the tumor, which blocks immune cell access, leading to suboptimal treatment outcomes for patients [2]. Group 2: Treatment Implications - The study suggests that a drug commonly used for migraine treatment can enhance the effectiveness of immune therapy by inhibiting sensory nerves, thereby weakening the barrier and allowing immune cells to enter the tumor [2][4]. - This innovative approach represents a shift towards utilizing existing clinical drugs in new ways to improve cancer treatment outcomes, potentially shortening the clinical translation cycle [4]. - The findings emphasize the need for a holistic view of cancer treatment that integrates the roles of nerves, tumors, and immune responses, paving the way for more precise therapies for breast cancer [4].